Holbrook Kohrt, MD, PhD; Pamela Kunz, MD Stanford University Cancer Center
- Status: Completed
- Year(s): 2015
- Research Type: Clinical
- Primary Tumor Site: Other
- Area of Inquiry: Clinical trials
The ultimate goal of this project is to identify tumor-immune biomarkers that represent prognostic, predictive, and therapeutically actionable targets in patients with neuroendocrine tumors. A tumor’s capacity to evade and suppress the immune response is a well-established hallmark of cancer. That harnessing the immune response could result in cure of a subset of patients with cancer is a revolution in cancer therapy. However, determining the potential of immunotherapy to be efficacious for patients with NETs necessitates an understanding of the tumor-immune phenotype which today remains unknown.
- To characterize the tumor-immune phenotype including a comprehensive immune profile and tumor genome utilizing the Stanford neuroendocrine tumor tissue microarray that includes 1031 tumors from 690 neuroendocrine tumor patients.
- To (a) characterize the tumor-immune phenotype including a comprehensive immune profile and tumor genome in serial samples among 20 patients enrolled in a Stanford investigator-initiated clinical trial of intratumoral anti-CTLA4 (ipilimumab) immunotherapy with anti-PD-L1 (MPDL3280A) in patients with well-differentiated, progressive neuroendocrine tumors.
- State: California
- Grant Duration: 1 years
- Awards: No information
NETRF funds laboratory research to understand the development of neuroendocrine tumors and translational research to explore new concepts in treatment. Research grant descriptions and research updates from NETRF are not intended to serve as medical advice. It can take years for research discoveries to be fully validated and approved for patient care. Always consult your health care providers about your treatment options.